In Times of Public Health Crisis, Vulnerable Consumers Look to Us for Sound Advice
By Mark Land, AAHP President | I have experienced many infectious disease crises thus far in my lifetime and each one was characterized by fear and uncertainty…
Read MoreMember Meeting Recap: cGMPs, Draft Guidance, & More from AAHP
By Eric Foxman. AAHP Secretary | AAHP held a very successful Annual Member Meeting on March 6 using a video-conferencing application…
Read MoreAre RCTs Really the Gold Standard of Evidence?
By Steve Mann, Director of External Regulatory Affairs, A Nelson & Co. Ltd. | Rarely do I get the opportunity to peruse the latest medical and scientific journals these days but, through some recent project work…
Read MoreOnline Opportunities and Responsibility
By Mark Land, AAHP President As our article on online marketing techniques shows, there’s great opportunity to increase product awareness and sales. But take caution; Do not do so at…
Read MoreHomeopathy Consumers Are Online. Are You?
Online Marketing Techniques for Homeopathic Manufacturers | Many of today’s consumers are looking for natural, safe, and effective drug products—and that means they’re turning to homeopathy. In fact, at our Summit event last spring, industry consulting firm The Emerson Group shared recent homeopathy sales numbers of $1.1 billion!
Read More3 Homeopathic Compliance Hot Spots to Watch
All drug products, homeopathic and allopathic alike, must be safe and effective. That means they have to be manufactured correctly, containing only the ingredients and potencies they claim to have. In short, all drugs must comply with Current Good Manufacturing Practice (CGMP). It is not only FDA’s responsibility to ensure these medications fulfill the CGMP requirements of safety, identity, strength, quality, and purity—it’s the industry’s responsibility, too.
Read MoreHow to Submit Monographs to the HPUS
FDA’s Revised Draft Enforcement Document states the Agency considers only products that use substances monographed in the Homeopathic Pharmacopoeia of the United States (HPUS) as homeopathic. This statement has created interest…
Read MoreFDA Comment Period Extended: Help AAHP Present Manufacturers’ Voice
AAHP is preparing comments to “FDA Drug Products Labeled as Homeopathic; Draft Guidance for Food and Drug Administration Staff and Industry.” Initially published in December 2017, the guidance was revised and republished…
Read MoreAAHP’s Views on Aspects of FDA’s Revised Draft Guidance
Since 2015, the Food and Drug Administration (FDA) has been engaged in a reevaluation of Compliance Policy Guide 400.400, Conditions under Which Homeopathic Drugs May Be Marketed. FDA issued a…
Read MoreAAHP 2019: Reawakening the Regulatory and Retail Dialog
By Mark Land, AAHP President This year marks the fifth year in a cycle of regulatory review of homeopathic drug product labeling, safety, and quality. AAHP has been there for…
Read More